ClinicalTrials.gg
RecruitingNCT07627815Updated Jun 4, 2026

Evaluating the Safety and Efficacy of PNMR as Treatment for Long COVID

A Phase 2 interventional study of Paragon Novel Metabolic Regulator (PNMR) and Dietary and Lifestyle Recommendations in Long COVID, sponsored by ParagonClinicals Inc.. Recruiting at 4 sites in Canada. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-06-04.

Sponsored by ParagonClinicals Inc. · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
82
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 40 studies in Post-Acute COVID-19 Syndrome with a site in Canada — 14 open to participants now, 17 under way, 3 of them phase 3. Post-Acute COVID-19 Syndrome · Canada.

Planned enrollment
17th of 33
82 · median 82
Started
2026
with 4 others
Phase 2
3 of 40
1 open now
Primary completion
2026-08
later than 5 of 16 live
Registered
40th of 40
by date

Among the 40 studies in Post-Acute COVID-19 Syndrome with a site in Canada, this one is the 17th largest by planned enrollment of the 33 interventional ones that give a count, is one of 5 that started in 2026, is one of 3 in phase 2, reaches primary completion later than 5 of the 16 other live ones, and was the 40th registered.

Post-Acute COVID-19 Syndrome

606 studies on the registry are indexed under Post-Acute COVID-19 Syndrome; 201 are open to participants now.

Browse Post-Acute COVID-19 Syndrome studies →

Open to participants now

14 of the 40 studies in Post-Acute COVID-19 Syndrome with a site in Canada are open now. Recruiting first, the newest first:

8 more — sign in →

All 14 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 144 Post-Acute COVID-19 Syndrome studies recruiting now, 69 (48%) set no upper age limit and 53 (37%) stop at 75 or younger; 15 take children under 18; 39 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies in Post-Acute COVID-19 Syndrome with a site in Canada, or all of them as a file.
02

Study summary

This will be a six-week, randomized, parallel, two group, open-label design. Patients will be treated with Paragon Novel Metabolic Regulator (PNMR) + standard of care (SOC) or SOC alone for 6 weeks for the treatment of Long COVID. All patients will also be provided with with Dietary \& Lifestyle recommendations specifically designed to enhance immune system function and reduce viral proliferation.

Patients will be assessed in the clinic at screening/baseline, 3 and 6 weeks while on treatment, and by telephone at 4 weeks post-treatment.

All patients will be asked to fill in a diary to record their daily treatment dosage when being treated with PNMR + SOC or with SOC alone. Primary objective: To evaluate the efficacy of PNMR + (SOC) vs. SOC in the treatment and management of patients with long COVID.

Read the detailed description

Because:

  • A) \~ 55% of patients have healed from long COVID, but have only been cured via a gradual, natural restoration of that patient's previously depleted endogenous mitochondrial and immune system function, and that
  • B) a fully-functioning immune system comprises the only known comprehensive system of cellular-driven mechanisms which make it capable of: neutralizing almost any pathogen(s); metabolizing and clearing systemic necrotic and fibrotic tissues occurring from injury; then healing those tissues and organs; and restoring normal signaling within the body's cells; to reverse as many as 300 different chronic symptoms that can affect a patient with long COVID,

And because metabolic research shows:

  • that long COVID patients are depleted of key nutrient metabolites enabling immune system and mitochondrial function, thereby making them unable to mount a properly regulated immune response,
  • and that COVID-19 and long COVID patients are depleted of specific amino acids and other metabolites compared to those fully recovered from COVID-19, whose metabolite levels have recovered to normal levels,
  • therefore: without the necessary balance of metabolites to rapidly and fully activate that patient's mitochondrial and immune system metabolism, many COVID-19 and long COVID patients cannot fully recover.
  • Further metabolic research also shows:
  • human cell systems maintain significant cellular storage levels of a wide range of essential nutrient metabolites supporting enzymes driving mitochondrial and immune system function and healing, all of which can be depleted by serious illness, and/or excessive exposure to any other toxic pathogens (whether industrial or environmental contaminants, pesticides, excess exposure to blue light, other harmful radiation, alcohol, drugs, certain Rx, lack of sleep, exercise stress, work stress, processed foods, refined sugars, nutritional imbalances, malnutrition, etc., and/or any combinations of the above), and that,
  • Affected cell systems and components (including the cytosol, mitochondria, associated metabolic pathways within cells, the lymphatic system, white blood cells, antibodies, antimicrobial peptides, defensins, and other compounds) require specific concentrations and ratios of specific amino and fatty acids - and corresponding concentrations and ratios of a wide range of specific metabolites - that together enable their continuous enzyme-driven metabolism within those cell systems.
  • This is possible because those enzyme systems are operating at speeds up to a million X faster than typical random chemical reaction. Further, the 1500-4000 interdependent enzymes found within each cell type all work together to supply byproduct from one enzyme reaction as input substrate to another in high-speed harmony to drive the metabolism of each cell type.
  • Therefore, anything disrupting the inflow of enzyme activators or substrates necessarily negatively impacts the flow of enzyme chemical byproduct output, and can seriously disrupt or dysregulate the entire enzyme matrix within the cell, and various organs, tissues and/or other physiological systems affected.
  • And therefore, when the body is subjected to excess pathogenic microbes or any other type of toxin listed above, the body's mitochondria and immune system cells have to work longer and harder to neutralize pathogens, detoxify and rebuild tissues,
  • and therefore, to maintain homeostasis, the body must consume higher levels of essential nutrient metabolites and other co-enzyme factors supporting this critical enzyme activity. If any of the essential nutrient metabolites supporting that enzyme activity is deficient or depleted, the proteome (net sum of enzymes in the body) supporting mitochondrial and immune system function can be significantly and negatively impacted.
  • Therefore: the PNMR was specifically designed to replenish those intracellular reserves of nutrient metabolites supporting this comprehensive endogenous mitochondrial and immune system function described above:
  • The PNMR capsules (provided in 1 - 6 packets per day, based on a patient's individual deficiency symptoms and needs) are designed to quickly restore optimum and balanced intracellular storage levels of those essential metabolites driving the balanced intracellular enzyme activity and metabolism required to maintain mitochondrial and immune system function, healing, and homeostatic regulation.
  • Further, this specific trial design is somewhat unusual - and is necessary - because there has never been a disease in modern human history like long COVID:
  • which is continuing to have unprecedented detrimental effects on human health and all national economies around the world,
  • is being driven by variants at least 12 X more infectious than the original Wuhan virus,
  • which results in viral persistence within tissues in those with even mild long COVID, which continues to mutate new COVID-19 variants in the entire global population with long COVID (and those with acute COVID-19), with the mutation rate measured to be \~ 1 mutation every 5 days in one long COVID patient in isolation in Germany,
  • with research showing repeat COVID-19 infections increase the probability of developing long COVID,
  • which is causing long COVID to spread quickly to all parts of the world, and is now estimated to have affected as many as 36% of all people who have had COVID-19, with just under half who contracted it who are not healing.
  • with no simple, approved testing method to quickly diagnose long COVID,
  • and based on Nov 2024 research from Harvard/Mass General Brigham (which used AI to help identify signs of long COVID, track symptom manifestation over time, and eliminate alternative explanations for 300,000 patients' symptoms) the data suggests that 22.8% of that population experience long COVID symptoms, a figure that may paint a more realistic picture of the pandemic's long-term toll and global reach.
  • And as most patients infected with long COVID globally have milder symptoms, and are not aware of their infection and its potential to cause serious clotting disorders, as well as other serious complications, or that they are actively mutating new COVID-19 variants - some which may mutate to a COVID-19 variant of concern (VOC) via convergent evolution,
  • and therefore, if the PNMR is proven to be successful reversing long COVID disease, as well as the mutation of new COVID variant mutations within such long COVID patients,
  • and therefore, if the world's goal is to reduce the current global levels of COVID-19 VOC transmission - then it's estimated that 75-85% of the 20-35% of the global population with long COVID will need to receive the PNMR treatment, to achieve the global herd immunity necessary to finally eradicate 75-85% of long COVID globally, which would thereby eradicate the vast majority of the rampant current mutation and transmission of new COVID-19 VOC from within long COVID patients globally, and thereby, very dramatically reduce global COVID-19 VOC transmission. When 75% - 85% of the world's population are immune to COVID viral infection, it may be possible to finally eradicate the transmission of COVID-19 virus, and ultimately eradicate the COVID-19 strains of virus.
  • Therefore, the critical importance of all factors above makes it equally important to design a PNMR Phase II trial that:
  • 1) clearly demonstrates the PNMR is essential to a rapid cure of chronic, systemic long COVID disease and tissue damage,
  • 2) while also demonstrating the combination of confounding dietary \& lifestyle factors that enable an even more rapid reversal - to demonstrate to the world the most effective use of this new class of medicine to most rapidly reverse disease.

This is why the Dietary and Lifestyle Recommendations, which have been demonstrated by peer-reviewed research to benefit those with chronic viral infections causing mitochondrial \& immune system dysfunction, are being provided to both the control \& treatment groups in the trial. This gives both patient groups in the trial potential mechanisms for healing.

And while initial medical case studies indicate the ingredients in the PNMR potentially represent a powerful curative treatment for the chronic tissue \& organ damage many long COVID patients have, effective dietary \& lifestyle measures are critical to further accelerating this healing process.

  • Further, because there is no treatment yet approved for long COVID, there is no approved standard of care (SOC) for long COVID:
  • therefore, the trial's design, and patient evaluations performed at Day 0 upon screening, Day 21 (end of week 3) midway through treatment, and at Day 42 (end of week 6) upon termination of treatment, allow the evaluation of 3 distinct levels of treatment on a long COVID patient's physical and mental function:
  • A) SOC (no treatment) prior to the trial: On Day 0, upon screening, up to 82 patients who've not received any long COVID treatment will be evaluated, establishing a baseline for patients without treatment,
  • Then upon evaluation, those up to 82 patients will then be randomly split into 2 groups:
  • B) Group 1 of up to 41 patients will receive PNMR treatment + SOC + Dietary \& Lifestyle Recommendations and be evaluated at the end of 3 \& 6 weeks, establishing potential for improvement with PNMR + Dietary and Lifestyle Recommendations,
  • C) Group 2 of up to 41 patients will receive SOC + Dietary \& Lifestyle Recommendations and be evaluated at 3 \& 6 weeks, establishing potential for improvement with Dietary \& Lifestyle Recommendations alone.
  • Therefore, this trial design will evaluate whether:
  • the group receiving the Dietary and Lifestyle Recommendations alone sees some improvement over no treatment, or SOC alone,
  • the group receiving the PNMR + the Dietary and Lifestyle Recommendations sees an even greater improvement over no treatment, or SOC alone.
03

Conditions studied

  • Long COVID

Keywords

  • Covid-19
  • Brain Fog
  • Chronic Fatigue
  • Post Exertional Malaise
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria: The patient must meet all the following criteria to be enrolled in the study:

  1. ≥19 years of age.
  2. Negative COVID-19 test for a minimum of four (4) weeks prior to enrollment in the study.
  3. Confirmed COVID-19 diagnosis by Polymerase chain reaction (PCR) test, antibody test, or clinical diagnosis more than four (4) weeks prior to enrollment in the study.
  4. Long COVID diagnosis according to the WHO criteria, specifically the continuation or development of new symptoms three months after the initial SARS-COV-2 infection, with these symptoms lasting for more than two months with no other explanation.
  5. For women of involved in any sexual intercourse that could lead to pregnancy: Negative pregnancy test and willingness to use (consistent with local regulations) during the study period. Approved contraceptive methods include contraceptive pills or patches, hormonal implants, intrauterine device (IUD), diaphragm or cervical cap with spermicide, and condos with spermicide.

    Note: If participant become pregnant during the study, they must stop taking the study products immediately and inform the study investigator.

  6. Patient agrees to stop taking any over the counter supplements, vitamins, or natural products as well as any of the prohibited medications during the study.
  7. Patient agrees not to use medications affecting directly (or potentially) the objectives of the study such as fatigue and cognitive function during the study.
  8. Willing to adhere to the study diet and exercise recommendations to the best of the patient's ability.
  9. Willing to complete the 6MWT.
  10. Willing to complete the patient self-administered questionnaires and diaries.
  11. Signed form by any patient capable of giving consent, or, when the patient is not capable of giving consent, by his or her legal/authorized representatives.

Exclusion Criteria:

  1. Subject is a female who is breastfeeding or pregnant or trying to conceive.
  2. Subject with a vegetarian diet or not able to follow the dietary guidelines.
  3. Known to PNMR or its ingredients.
  4. Participating in other drug clinical trials (participation in COVID-19 antiviral trials may be permitted if approved by sponsor).
  5. Any condition that in the opinion of the investigator participation in the trial increases the risk to the patient.
  6. 4 weeks or more of consecutive daily supplement use of 5000 IUs Vitamin D / day and/or 50mg Zinc (without copper) / day within 4 weeks of Day 0.
  7. Use of any medications or treatments for which treatment with PNMR is counter-indicated.
  8. Subject is not able to swallow a larger number of capsules.
  9. Any condition that in the opinion of the investigator would confound the study results or would prevent the patient to complete the study.
  10. Any patient for whom vitamin D3 (cholecalciferol) is per the following patient situations:

    1. Hypersensitivity to vitamin D, any of its analogues and derivatives or to any ingredient in the formulation
    2. Hypercalcemia and/or hypercalciuria
    3. Nephrolithiasis (renal calculi)
    4. Severe renal impairment ( \<30)
    5. Malabsorption syndrome
    6. Abnormal sensitivity to the toxic effects of vitamin D
    7. Sarcoidosis
    8. Hypervitaminosis D
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
82 participants (estimated)

Study arms

  • Experimental
    Group 1: PNMR + Dietary and Lifetyle Recomendations + Standard of Care (SOC)

    Patients in Group 1 are instructed to take 2 PNMR packs on Day 1 and evaluate and adjust their daily PNMR dosage from Day 2 to Day 42 of their 6-week treatment period up to a maximum of 6 packs per day based on the presence of long COVID symptoms. Patients lower the dosage by 1 pack /day based upon signals showing the body is healing (and has replenished its depleted sulfur protein nutrient stores - required for energy production and healing), as seen with a temporary release of sulfur-smelling flatulence, or rarely unpleasant dreams, if the patient no longer needs as much medicine. Patients maintain a minimum dosage of no less than 1 pack per 2 days. Patients are instructed to take PNMR 5-20 minutes before eating, 3-6 capsules at a time, with water. Patients in Group 1 are also given specific dietary and lifestyle recommendations. Patients receiving PNMR will additionally be treated with SOC as per the regional guidelines and the decision of the treating physician.

    Drug: Paragon Novel Metabolic Regulator (PNMR) · Other: Dietary and Lifestyle Recommendations

  • Experimental
    Group 2: Dietary and Lifetyle Recomendations + Standard of Care (SOC)

    Patients in Group 2 will be given specific dietary and lifestyle recommendations. Patients receiving PNMR will additionally be treated with SOC as per the regional guidelines and the decision of the treating physician.

    Other: Dietary and Lifestyle Recommendations

Interventions

  • DrugParagon Novel Metabolic Regulator (PNMR)

    Research shows human cell systems maintain significant cellular storage levels of a wide range of critical metabolites supporting enzymes driving mitochondrial and immune system function and healing, all of which can be depleted by serious illness. Such cell systems and components (including the cytosol, mitochondria, metabolic pathways within cells, white blood cells, antibodies, antimicrobial peptides, enzymes, and other compounds) require specific concentrations of specific amino and fatty acids - and corresponding concentrations of a wide range of specific metabolites - that together enable their continuous metabolism within those cell systems. The PNMR capsules (provided in 1 - 6 packets per day) are designed to quickly restore optimum and balanced cellular storage levels of those critical metabolites driving the balanced intracellular enzyme activity and metabolism required to maintain mitochondrial and immune system function, healing, and homeostatic regulation.

  • OtherDietary and Lifestyle Recommendations

    Dietary and Lifestyle Recommendations specifically designed to enhance immune system function and reduce viral proliferation

06

What researchers measure

Primary outcomes

  1. Change in distance walked on the 6-minute walk test (6MWT) after 6 weeks of treatment.

    Patient baseline is first assessed at Day 0 upon screening, and then retested after 6 weeks of treatment.

    Time frame: From enrollment to the end of treatment at 6 weeks

Secondary outcomes

  1. Change in distance walked on the 6MWT after 3 weeks of treatment.

    Time frame: From enrollment to the completion of 3 weeks initial treatment.

  2. Proportion of patients achieving an improvement of 30 meters or more on the 6MWT by 3 and 6 weeks on treatment.

    Time frame: From enrollment to measurements made at 3 and 6 weeks

  3. Time to achieving an improvement of 30 m or more on the 6MWT by 6 weeks on treatment.

    Time frame: From enrollment to measurements made at either 3 or 6 week if achieved

  4. Change in patient-reported assessment of fatigue on a 100 mm visual analogue scale (VAS) at 3 and 6 weeks on treatment.

    Fatigue Severity over the last 7 days, reported on a 100 mm Visual Analogue Scale: 0 - 100, higher score means a worse outcome

    Time frame: From enrollment assessment to assessments made at 3 and 6 weeks

  5. Change in patient-reported assessment of brain fog duration at 3 and 6 weeks on treatment.

    Brain Fog Duration seen over last 7 days: 0 - 7 days, higher score means a worse outcome

    Time frame: From enrollment assessment to assessments made at 3 and 6 weeks

  6. Change in patient-reported assessment of brain fog severity on a 100 mm VAS at 3 and 6 weeks on treatment.

    Brain Fog Severity over the last 7 days reported on a 100 mm Visual Analogue Scale: 0 - 100, higher score means a worse outcome

    Time frame: From enrollment assessment to assessments made at 3 and 6 weeks

  7. Change in QoL as measured by the Medical Outcomes Study Short Form 36 (SF-36) at 3 and 6 weeks on treatment.

    The SF-36 (Short Form 36) is a self-reported survey that measures 36 individual health-related indicators of Quality of Life (QOL). It asks the patient to rate their: General Health; General Health now compared to one week ago; along with more detailed evaluations of Physical Health, Role Limitations (Physical), Emotional Health, Role Limitations (Emotional), Social Functioning; and to rate other factors related to Pain, Energy, and Mood as compared to the week prior. Each question has a unique set of answers specific to the question. For some questions a higher score means a worse outcome, whereas for other questions a higher score means a better outcome. This method requires that the patient think through each answer individually.

    Time frame: From enrollment measurement to measurements made at 3 and 6 weeks

  8. Health care utilization at 3 and 6 weeks on treatment.

    Health care utilization at 3 and 6 weeks on treatment. * Physician visits * Clinic visits * Other health care professional visits and consultations * Prescription medication use for the management of flu or flu-like illness * Non-prescription medication use for the management of flu or flu-like illness

    Time frame: Health care utilization measured at 3 and 6 weeks on treatment.

Other outcomes

  1. Number of treatment-emergent adverse events (TEAEs) and serious TEAEs.

    Time frame: Realized from enrollment to completion of treatment at 6 weeks

07

Study locations

4 of 4 sites recruiting
  • Cardio Health
    Brampton, Ontario L6Y 6H4, Canada
    Recruiting
  • Cardio Health
    London, Ontario N6G 5C2, Canada
    Recruiting
  • Cardio Health
    Mississauga, Ontario L5M 2S6, Canada
    Recruiting
  • Cardio Health
    North York, Ontario M3N 2K1, Canada
    Recruiting
    • Mala Singh · Contactmala@cardio-health.ca · 905-882-4848
    • Emma Benedict, MD · Principal investigator
08

References and documents

Publications

  • Al-Aly Z, Davis H, McCorkell L, Soares L, Wulf-Hanson S, Iwasaki A, Topol EJ. Long COVID science, research and policy. Nat Med. 2024 Aug;30(8):2148-2164. doi: 10.1038/s41591-024-03173-6. Epub 2024 Aug 9. PubMed 39122965 ↗
  • Castanares-Zapatero D, Chalon P, Kohn L, Dauvrin M, Detollenaere J, Maertens de Noordhout C, Primus-de Jong C, Cleemput I, Van den Heede K. Pathophysiology and mechanism of long COVID: a comprehensive review. Ann Med. 2022 Dec;54(1):1473-1487. doi: 10.1080/07853890.2022.2076901. PubMed 35594336 ↗
  • Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. 2023 Mar;21(3):133-146. doi: 10.1038/s41579-022-00846-2. Epub 2023 Jan 13. PubMed 36639608 ↗

Individual participant data

Plan to share: Yes — All IPD that underlie results in a publication.

Supporting information: Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: Beginning 3 months and ending 3 years after the publication of results

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Aug 2026, 3 months after the start.

Of 63 phase 2 interventional studies under Post-Acute COVID-19 Syndrome, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 23. This study's planned 3 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 24, 2026
First posted
Jun 4, 2026
StartActual
May 20, 2026
Primary completionEst.
Aug 26, 2026
CompletionEst.
Dec 26, 2026
Last update
Jun 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07627815
Lead sponsor
ParagonClinicals Inc.
Responsible party
Sponsor
First posted
Jun 4, 2026
Start date
May 20, 2026
Primary completion
Aug 26, 2026 (estimated)
Completion
Dec 26, 2026 (estimated)
Last update
Jun 4, 2026

Study contacts

Samuel H. O. Bock / CSO, BA Environmental Science
Contact
sbock@paragonsciences.com
514 998-3935
John S Sampalis, PHD Epidemiology
Contact
jsampalis@jssresearch.com
514 934-6116
Sam Bock, BA Environmental Science
study director · ParagonClinicals Inc CEO / CSO

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion